200 related articles for article (PubMed ID: 29721482)
1. Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.
Gupta S; Singh M; Vora A; Babu G; Walia M; Nautial V; Saha R; Smruti BK; Sharma JB; Koul R; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):142-145. PubMed ID: 29721482
[TBL] [Abstract][Full Text] [Related]
2. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer.
Bharatuar A; Kar M; Khatri S; Goswami V; Sarin R; Dawood S; Iyenger R; Ganvir M; Parikh PM; Aggarwal S; Talwar V
South Asian J Cancer; 2018; 7(2):91-95. PubMed ID: 29721471
[TBL] [Abstract][Full Text] [Related]
5. Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).
Singhal M; Sahoo TP; Aggarwal S; Singhvi A; Kaushal V; Rajpurohit S; Parthasarthi KM; Vora A; Ganvir M; Gupta S; Parikh PM
South Asian J Cancer; 2018; 7(2):151-155. PubMed ID: 29721484
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
7. Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
Aggarwal S; Vaid A; Ramesh A; Parikh PM; Purohit S; Avasthi B; Gupta S; Ranjan S; Kaushal V; Salim S; Singh R; Minhas S; Doval D
South Asian J Cancer; 2018; 7(2):96-101. PubMed ID: 29721472
[TBL] [Abstract][Full Text] [Related]
8. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
9. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Rocchi A; Verma S
Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
12. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
Ligibel JA; Winer EP
J Natl Compr Canc Netw; 2003 Apr; 1(2):215-21. PubMed ID: 19768880
[TBL] [Abstract][Full Text] [Related]
13. Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women.
Babu G; Goel A; Agarwal S; Gupta S; Kumar P; Smruti BK; Goel V; Sarangi R; Gairola M; Aggarwal S; Parikh PM
South Asian J Cancer; 2018; 7(2):123-126. PubMed ID: 29721478
[TBL] [Abstract][Full Text] [Related]
14. Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer.
Rajappa S; Bajpai J; Basade M; Ganvir M; Goswami C; Murali A; Rathi AK; Kaushal V; Jain S; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):137-141. PubMed ID: 29721481
[TBL] [Abstract][Full Text] [Related]
15. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
16. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
17. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
18. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
Chung CT; Carlson RW
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
